Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Mantle-Cell 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 9Waldenstrom Macroglobulinemia 8Lymphoma 8Lymphoma, B-Cell, Marginal Zone 7Leukemia, Myeloid, Acute 7Leukemia 7Hodgkin Disease 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 6Lymphoma, Large-Cell, Anaplastic 6Immunoblastic Lymphadenopathy 6Burkitt Lymphoma 6Sezary Syndrome 5Mycosis Fungoides 5Multiple Myeloma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma, T-Cell, Cutaneous 4Recurrence 3Neoplasms, Plasma Cell 3Lymphoma, Large-Cell, Immunoblastic 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hematologic Neoplasms 3Primary Myelofibrosis 2Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphoma, B-Cell 2

Interventions

Cyclophosphamide 207fludarabine phosphate 182Azacitidine 153fludarabine 141Busulfan 139Tacrolimus 118Mycophenolic Acid 111Cytarabine 110Whole-Body Irradiation 105Peripheral Blood Stem Cell Transplantation 97Antilymphocyte Serum 95Melphalan 89Filgrastim 86Cyclosporine 81Methotrexate 78Decitabine 78venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 46Cord Blood Stem Cell Transplantation 43thymoglobulin 41Clofarabine 41Etoposide 35Specimen Handling 34Methylprednisolone 34Sirolimus 33Biopsy 27Injections 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Everolimus × Other hematologic neoplasm × Clear all
NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡